Completion of financing totaling 1,746 million yen

J-Pharma Co., Ltd. (Headquarters: Tsurumi-ku, Yokohama-shi, Kanagawa, President and
CEO Masuhiro Yoshitake) has implemented a third-party allocation of new shares to the
following 16 companies as Round D by July 30, 2020. We are pleased to inform you that
we have raised a total of 1,746 million yen.

Newton Biocapital SA
Spera Pharma Co., Ltd.
Ohara Pharmaceutical Co., Ltd.
Osaka University Venture Capital Co., Ltd. Mitsubishi UFJ Capital Co., Ltd.
SR D Holdings Co., Ltd.
QB Capital LLC
MBL Venture Capital Co., Ltd.
Iwagin Business Creation Capital Co., Ltd.
KNC Laboratories Co., Ltd.
Sansei Capital Co., Ltd.
Mizuho Capital Co., Ltd.
Japan Venture Capital Co., Ltd.
KSP Co., Ltd.
Fidea Capital, Ltd.

In the future, we will promote the clinical development of JPH203 for biliary tract cancer,
the clinical development of OKY034 for pancreatic cancer, and the application of LAT1
inhibitors to autoimmune diseases, which are currently under clinical trials.
We will make the best use of our high expertise and wide range of connections to prove new
drug targets originating in Japan through rigorous clinical trials, and to provide medical
care through collaboration with companies not only in Japan but also overseas.
We will actively promote the application.

[Contact for inquiries regarding this topic]
J-Pharma Co., Ltd.
Corporate Planning Department
Tel: 045-506-1155
Fax: 045-506-1156
Person in charge: Bamba